Director Diem Nguyen awarded 32,000 Candel Therapeutics (CADL) stock options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Candel Therapeutics director Diem Nguyen received a stock option grant for 32,000 shares of common stock. The options have an exercise price of $9.0800 per share and expire on June 23, 2036. They vest upon the earlier of June 23, 2027 or the company’s next annual stockholder meeting, so long as Nguyen continues serving on the board.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Nguyen Diem

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	32,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 32,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Option grant size: 32,000 shares Exercise price: $9.0800 per share Expiration date: June 23, 2036 +2 more

5 metrics

Option grant size 32,000 shares Stock Option (Right to Buy) awarded to director

Exercise price $9.0800 per share Strike price of stock option grant

Expiration date June 23, 2036 Option expiration

Vesting date trigger June 23, 2027 Earlier of this date or next annual meeting

Total options after grant 32,000 shares Total derivative securities following transaction

Key Terms

Stock Option (Right to Buy), time-based vesting, Annual Meeting of Stockholders, Board of Directors

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

time-based vesting financial

"This option is subject to time-based vesting."

Time-based vesting is a schedule that gives employees or contractors ownership of granted stock or options gradually as they remain with a company, like unlocking rewards in a loyalty program the longer you stick around. For investors, it matters because it affects future share supply, management incentives and staff retention — all of which can influence company performance and dilution of existing shareholders.

Annual Meeting of Stockholders financial

"the date of the next Annual Meeting of Stockholders of the Issuer"

Board of Directors financial

"resigns from the Board of Directors (the "Board") of the Issuer"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/24/2026 - 04:27 PM Accepted by SEC EDGAR 06/24/2026 - 04:27 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nguyen Diem

(Last)

(First)

(Middle)

C/O CANDEL THERAPEUTICS, INC.

117 KENDRICK ST., SUITE 450

(Street)

NEEDHAM

MASSACHUSETTS

02494

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Candel Therapeutics, Inc. [ CADL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$9.08	06/23/2026		A		32,000		⁽¹⁾	06/23/2036	Common Stock	32,000	$0	32,000	D

Explanation of Responses:

1. This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting.

	/s/ Charles Schoch, as Attorney-In-Fact for Diem Nguyen	06/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Candel Therapeutics (CADL) report for Diem Nguyen?

Candel Therapeutics reported a grant of stock options to director Diem Nguyen covering 32,000 shares of common stock. These options give the right to buy shares at a fixed price if vesting and other conditions are met.

How many Candel Therapeutics (CADL) shares are covered by Diem Nguyen’s new options?

The new stock option grant covers 32,000 underlying shares of Candel Therapeutics common stock. This figure also reflects Nguyen’s total option holdings for this award immediately after the transaction, according to the reported Form 4 data.

What is the exercise price of Diem Nguyen’s Candel Therapeutics (CADL) stock options?

The stock options granted to Diem Nguyen have an exercise price of $9.0800 per share. This means Nguyen can purchase Candel Therapeutics common stock at that fixed price once the options vest and become exercisable.

When do Diem Nguyen’s Candel Therapeutics (CADL) options vest?

The options vest upon the earlier of June 23, 2027 or the date of Candel Therapeutics’ next annual stockholder meeting. Vesting continues only while Nguyen remains on the board, unless the board decides to allow continued vesting.

When do Diem Nguyen’s Candel Therapeutics (CADL) options expire?

The granted stock options expire on June 23, 2036. After that expiration date, any unexercised portion of the 32,000-share option grant can no longer be used to purchase Candel Therapeutics common stock.

Are Diem Nguyen’s Candel Therapeutics (CADL) options immediately exercisable?

The options are subject to time-based vesting and are not fully exercisable immediately. They become exercisable when vesting occurs, which is scheduled for the earlier of June 23, 2027 or the next annual stockholder meeting, assuming board service continues.